The Global Dermatophytic Onychomycosis Treatment Market Size Was Valued At USD 3.74 Billion In 2022 And Is Projected To Reach USD 6.63 Billion By 2030, Exhibiting A CAGR Of 7.4% During The Forecast Period.

Dermatophytic Onychomycosis Treatment Market Overview:

Onychomycosis (OM) is a fungal infection of the nails that results in discoloration and thickening of the nails. It accounts for about one-third of all fungal infections worldwide. Also, about 70% to 80% of all onychomycosis infections are caused by dermatophytes. This increase in prevalence has increased the demand for dermatophyte onychomycosis drugs. Moreover, the increased prevalence of diabetes increases the risk of developing nail fungus infections. According to an article published in Podiatry Management, people with diabetes have a 2.77 times the risk or odds of developing OM. Additionally, increasing research and rapid adoption of nail lacquers is expected to boost the market during the forecast period.

Rather, the sudden pandemic of Corona 19 caused a lot of confusion and led to an economic crisis. As a result, the market growth rate also declined. Companies such as Kaken Pharmaceuticals Co., Ltd. have reported declining sales of their products. Additionally, uncertainty regarding the duration of the pandemic and restrictions on visits to healthcare facilities are expected to hinder market growth.

Dermatophytic Onychomycosis Treatment Market size, estimates and forecasts are provided in terms of sales volume (K units) and revenue (million USD), with historical and forecast data for the period 2017 to 2030, with 2022 being considered as the base year. This report segments the global Dermatophytic Onychomycosis Treatment Market in detail. Regional market sizes related to products by type, by application, and by player are also delivered. In estimating the size of the market, we took into account the impact of COVID-19 and the Russian-Ukraine war.

Key Market Updates:

• In July 2021, Almirall S.A. entered into a licensing and distribution agreement with Kaken Pharmaceutical. This will grant exclusive rights to develop and commercialize a topical formulation of efinaconazole in Europe.
• In November 2017, BRIEF-Kaken Pharmaceutical signed an exclusive sales agreement for Clenafin/Jublia in Taiwan. This agreement aims to accelerate product sales in Japan.
• In September 2016, Erchonia Corp. received 510(k) approval from the US FDA for its low-level lunula laser. It is the first low-level laser approved for the treatment of onychomycosis or toenail fungus.

Major Market Segments Covered in Dermatophytic Onychomycosis Treatment Market Industry Research:

Market Key Players:
Bausch Health Companies, Novartis AG, Johnson and Johnson, Galderma S.A., Celtic Pharmaceuticals, Anacor Pharmaceuticals, And Others.

By Product Type:

• Tablets
• Nail Paints

By Route of Administration:

• Oral
• Topical

By Type:

• Prescribed
• Over-the-Counter (OTC)

By Application:

• Hospitals & Clinics
• Retail Pharmacies
• Online Channels

By Region:

The US has an 84.4% market share in the North American dermatophyte onychomycosis treatment market. It occupied the highest market share in North America due to the increasing prevalence of chronic diseases such as diabetes.

According to the Diabetes Organization, nearly 34.2 million Americans went undiagnosed in 2018. In addition, social stigma and an aging population are increasing the demand for dermatophytoid onychomycosis treatment.

Germany is one of the top countries with high healthcare spending. The country accounted for 19% of the European dermatophyte onychomycosis treatment market share in 2021 and is expected to achieve steady growth at a CAGR of 6.9% over the coming years.

This high market share is due to the fact that many of the key players in this industry are active in Germany, increasing the availability of products in Germany.

In 2021, China's dermatophyte onychomycosis treatment market was valued at USD 134.1 million, accounting for a 34.9% market share in East Asia.

Healthcare infrastructure development and strategic planning to work together for expansion are key factors positively impacting the growth of this industry in China.

For example, in March 2021, Tianjin Institute of Pharmaceutical Research, a joint venture with HUYABIO International, submitted a New Drug Application (NDA) to the National Medical Products Administration's Center for Drug Evaluation. The application sought approval of the topical formulation Jublia™, an antifungal drug efinaconazole, for the treatment of onychomycosis, a skin disease.

These joint research activities will lead the Chinese market and provide lucrative opportunities for local manufacturers.

India accounted for 44.5% of the total value of the South Asian dermatophyte onychomycosis treatment market valued at USD 94.9 million in 2021.

India is one of the leading countries in pharmaceutical manufacturing. As major manufacturers continue to develop effective therapeutic agents, the increasing global burden of dermatophytosis onychomycosis disease and the associated increase in the proportion of patient pools for treatment will drive the demand for onychomycosis dermatophytosis therapeutics.

• North America
• US
• Canada
• Mexico
• Rest of North America
• Europe
• Germany
• France
• Italy
• Spain
• UK
• Nordic Countries
• Denmark
• Finland
• Iceland
• Sweden
• Norway
• Benelux Union
• Belgium
• The Netherlands
• Luxembourg
• Rest of Europe
• Asia-Pacific
• Japan
• China
• India
• Australia
• South Korea
• Southeast Asia
• Indonesia
• Thailand
• Malaysia
• Singapore
• Rest of Southeast Asia
• Rest of Asia-Pacific
• The Middle East & Africa
• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest of the Middle East & Africa
• Latin America
• Brazil
• Argentina
• Rest of Latin America

Significant Market Dynamics:

Restraints

Antifungal drugs used to treat onychomycosis, a skin disease, have certain side effects, such as headache, dizziness, nausea, and abdominal pain. In addition, external use may cause rashes and itching on the surrounding skin. These side effects are expected to hinder the growth of the global dermatophyte onychomycosis treatment market.

Additionally, the availability of alternative treatment options such as Vicks Vapor Listerine and Tea Tree Oil for treating nail infections is also expected to hamper the market growth.

Opportunities

Identification of the infectious agent in onychomycosis, at least at the genus level, plays an important role in the treatment regimen for dermatophytoid onychomycosis. Key players in the market may focus on developing dermatophyte strip tests for rapid detection and diagnosis of disease.

The growing geriatric population is also expected to provide lucrative growth opportunities for players in the global dermatosis onychomycosis treatment market. Toenail onychomycosis is common in people over the age of 60. According to the World Health Organization (WHO), the proportion of the world's population over the age of 60 was 12% in 2015 and is expected to reach 22% by 2050.

Dermatophytic Onychomycosis Treatment Market report scope:

Key Takeaways from this Dermatophytic Onychomycosis Treatment Market Report

• Estimate Dermatophytic Onychomycosis Treatment Market potential through analyzing growth rates (CAGR %), Volume (Units) and Value ($M) data given at country level - for product types, applications and by different industry verticals.
• Understand the supply chain in depth on the value growth at each step, in order to optimize value and bring effectiveness in your processes.
• Know the different dynamics affecting the market - challenges, key driving factors and opportunities.
• Get a quick viewpoint on the Dermatophytic Onychomycosis Treatment Market entropy - M&A's, deals, partnerships, product launches of all key companies for the historical 5 years.
• Estimate the supply-demand gaps, import-export data and regulatory landscape for more than top 20 countries worldwide for the market.
• Get complete insights on your competitor performance - market shares, strategies, financial benchmarking, product benchmarking, SWOT and more.
• Study the sales and distribution channels over key geographies to improve top-line revenues.

Frequently Asked Questions-

What is the CAGR of Dermatophytic Onychomycosis Treatment Market?

The Dermatophytic Onychomycosis Treatment Market is growing at a CAGR of 7.4% During Forecast Period.

 What are the key types of Dermatophytic Onychomycosis Treatment Market?

Prescribed, Over-the-Counter (OTC)

What are the key applications of Dermatophytic Onychomycosis Treatment Market?

Hospitals & Clinics, Retail Pharmacies, Online Channels

Who are the key players in Dermatophytic Onychomycosis Treatment Market?

Bausch Health Companies, Novartis AG, Johnson and Johnson, Galderma S.A., Celtic Pharmaceuticals, Anacor Pharmaceuticals, And others.